CA1222516A - Tricyclic compounds, and their preparation - Google Patents
Tricyclic compounds, and their preparationInfo
- Publication number
- CA1222516A CA1222516A CA000426692A CA426692A CA1222516A CA 1222516 A CA1222516 A CA 1222516A CA 000426692 A CA000426692 A CA 000426692A CA 426692 A CA426692 A CA 426692A CA 1222516 A CA1222516 A CA 1222516A
- Authority
- CA
- Canada
- Prior art keywords
- group
- formula
- tetrazolyl
- compound
- xanthone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 126
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 50
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- -1 5-tetrazolyl group Chemical group 0.000 claims abstract description 45
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000001301 oxygen Substances 0.000 claims abstract description 35
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 27
- 239000001257 hydrogen Substances 0.000 claims abstract description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005864 Sulphur Chemical group 0.000 claims abstract description 8
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 159000000000 sodium salts Chemical class 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 5
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 claims description 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- IVXIHYJYORUTFH-UHFFFAOYSA-N 2-(2-hydroxyethoxy)-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(OCCO)=CC=C3OC2=CC=1C=1N=NNN=1 IVXIHYJYORUTFH-UHFFFAOYSA-N 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- LFTOSGCSRGXFHR-UHFFFAOYSA-N 7-ethoxy-9-oxoxanthene-3-carbonitrile Chemical compound N#CC1=CC=C2C(=O)C3=CC(OCC)=CC=C3OC2=C1 LFTOSGCSRGXFHR-UHFFFAOYSA-N 0.000 claims description 2
- 230000021523 carboxylation Effects 0.000 claims description 2
- 238000006473 carboxylation reaction Methods 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- MPTIYRLFOQQXKE-UHFFFAOYSA-N 2-ethoxy-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(OCC)=CC=C3OC2=CC=1C=1N=NNN=1 MPTIYRLFOQQXKE-UHFFFAOYSA-N 0.000 claims 2
- RFEVLWLRJAZKCF-UHFFFAOYSA-N 2-[9-oxo-6-(2h-tetrazol-5-yl)xanthen-2-yl]oxyethyl acetate Chemical compound C=1C=C2C(=O)C3=CC(OCCOC(=O)C)=CC=C3OC2=CC=1C1=NN=NN1 RFEVLWLRJAZKCF-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 abstract description 14
- 210000003743 erythrocyte Anatomy 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 206010021143 Hypoxia Diseases 0.000 abstract description 5
- 230000007954 hypoxia Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 abstract description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 2
- 230000000747 cardiac effect Effects 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 2
- 150000001721 carbon Chemical group 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- 229910001868 water Inorganic materials 0.000 description 80
- 239000000243 solution Substances 0.000 description 67
- 239000000203 mixture Substances 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000008280 blood Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 31
- 239000007787 solid Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 238000010992 reflux Methods 0.000 description 20
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 238000009472 formulation Methods 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 238000006073 displacement reaction Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 235000011149 sulphuric acid Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 150000004682 monohydrates Chemical class 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000001117 sulphuric acid Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 5
- LKCYMRFUTJFFSP-UHFFFAOYSA-N 9-oxoxanthene-1-carbonitrile Chemical compound C1=CC(C#N)=C2C(=O)C3=CC=CC=C3OC2=C1 LKCYMRFUTJFFSP-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- YTYRBNMFLQCUEX-UHFFFAOYSA-N 2-methoxy-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(OC)=CC=C3OC2=CC=1C1=NN=NN1 YTYRBNMFLQCUEX-UHFFFAOYSA-N 0.000 description 3
- PESDKOMCZSYXAQ-UHFFFAOYSA-N 7-methoxy-9-oxoxanthene-3-carbonitrile Chemical compound N#CC1=CC=C2C(=O)C3=CC(OC)=CC=C3OC2=C1 PESDKOMCZSYXAQ-UHFFFAOYSA-N 0.000 description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical class [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229940116364 hard fat Drugs 0.000 description 3
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 239000012991 xanthate Substances 0.000 description 3
- 150000007964 xanthones Chemical class 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- PJUJNJLLEULKHR-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C1=C2C(=O)C3=CC=CC=C3OC2=CC=C1C1=NN=NN1 PJUJNJLLEULKHR-UHFFFAOYSA-N 0.000 description 2
- NCTJFWCHGUDCDM-UHFFFAOYSA-N 2-(4-ethylphenyl)sulfanylterephthalic acid Chemical compound C1=CC(CC)=CC=C1SC1=CC(C(O)=O)=CC=C1C(O)=O NCTJFWCHGUDCDM-UHFFFAOYSA-N 0.000 description 2
- WTIDGYMCRDXCGZ-UHFFFAOYSA-N 2-hydroxy-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(O)=CC=C3OC2=CC=1C1=NN=NN1 WTIDGYMCRDXCGZ-UHFFFAOYSA-N 0.000 description 2
- ALWLIOKDPPDELH-UHFFFAOYSA-N 2-methoxy-7-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C1=C2C(=O)C3=CC(OC)=CC=C3OC2=CC=C1C=1N=NNN=1 ALWLIOKDPPDELH-UHFFFAOYSA-N 0.000 description 2
- LKVFCSWBKOVHAH-UHFFFAOYSA-N 4-Ethoxyphenol Chemical compound CCOC1=CC=C(O)C=C1 LKVFCSWBKOVHAH-UHFFFAOYSA-N 0.000 description 2
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 2
- WERADRZIKXESBY-UHFFFAOYSA-N 7-methoxy-9h-xanthene-3-carboxylic acid Chemical compound OC(=O)C1=CC=C2CC3=CC(OC)=CC=C3OC2=C1 WERADRZIKXESBY-UHFFFAOYSA-N 0.000 description 2
- BXBRIJMDVNZJKZ-UHFFFAOYSA-N 7-methylsulfanyl-9h-xanthene-3-carboxylic acid Chemical compound OC(=O)C1=CC=C2CC3=CC(SC)=CC=C3OC2=C1 BXBRIJMDVNZJKZ-UHFFFAOYSA-N 0.000 description 2
- FHESISUYWMXGDO-UHFFFAOYSA-N 9h-xanthene-1-carbonitrile Chemical compound O1C2=CC=CC=C2CC2=C1C=CC=C2C#N FHESISUYWMXGDO-UHFFFAOYSA-N 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 2
- 229910000497 Amalgam Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 150000001411 amidrazones Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- RXMRGBVLCSYIBO-UHFFFAOYSA-M tetramethylazanium;iodide Chemical compound [I-].C[N+](C)(C)C RXMRGBVLCSYIBO-UHFFFAOYSA-M 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 150000003732 xanthenes Chemical class 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GCUZZGCJEFPWEU-UHFFFAOYSA-N (7-methylsulfanyl-9h-xanthen-3-yl)methanol Chemical compound OCC1=CC=C2CC3=CC(SC)=CC=C3OC2=C1 GCUZZGCJEFPWEU-UHFFFAOYSA-N 0.000 description 1
- PRLBQTCQXASBPV-UHFFFAOYSA-N (diazo-lambda4-sulfanylidene)-sulfanylmethanol Chemical compound OC(S)=S=[N+]=[N-] PRLBQTCQXASBPV-UHFFFAOYSA-N 0.000 description 1
- VCZVSAXHSAVTKM-UHFFFAOYSA-N 1-(6-cyano-9-oxoxanthen-2-yl)oxypropan-2-yl acetate Chemical compound N#CC1=CC=C2C(=O)C3=CC(OCC(C)OC(C)=O)=CC=C3OC2=C1 VCZVSAXHSAVTKM-UHFFFAOYSA-N 0.000 description 1
- TYVCGEVIYKZPEU-UHFFFAOYSA-N 1-aminoxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N TYVCGEVIYKZPEU-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- WBMYCQLXKJBBOG-UHFFFAOYSA-N 2-(2-hydroxypropoxy)-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(OCC(O)C)=CC=C3OC2=CC=1C1=NN=NN1 WBMYCQLXKJBBOG-UHFFFAOYSA-N 0.000 description 1
- GOKUACPITGTHTF-UHFFFAOYSA-N 2-(2-hydroxypropoxy)-6-(2h-tetrazol-5-yl)xanthen-9-one;sodium Chemical compound [Na].C=1C=C2C(=O)C3=CC(OCC(O)C)=CC=C3OC2=CC=1C=1N=NNN=1 GOKUACPITGTHTF-UHFFFAOYSA-N 0.000 description 1
- MTKQVQANCNNNCU-UHFFFAOYSA-N 2-(3-hydroxypropoxy)-6-(2h-tetrazol-5-yl)xanthen-9-one;sodium Chemical compound [Na].C=1C=C2C(=O)C3=CC(OCCCO)=CC=C3OC2=CC=1C=1N=NNN=1 MTKQVQANCNNNCU-UHFFFAOYSA-N 0.000 description 1
- RPSVSVVEBCQMDN-UHFFFAOYSA-N 2-(4-ethoxyphenoxy)terephthalic acid Chemical compound C1=CC(OCC)=CC=C1OC1=CC(C(O)=O)=CC=C1C(O)=O RPSVSVVEBCQMDN-UHFFFAOYSA-N 0.000 description 1
- KMCHTQHUSLEVNC-UHFFFAOYSA-N 2-(4-methoxyphenoxy)terephthalic acid Chemical compound C1=CC(OC)=CC=C1OC1=CC(C(O)=O)=CC=C1C(O)=O KMCHTQHUSLEVNC-UHFFFAOYSA-N 0.000 description 1
- VUSUSPDOEWNKCH-UHFFFAOYSA-N 2-(4-methylphenyl)sulfanylterephthalic acid Chemical compound C1=CC(C)=CC=C1SC1=CC(C(O)=O)=CC=C1C(O)=O VUSUSPDOEWNKCH-UHFFFAOYSA-N 0.000 description 1
- FCRFNKDATPMHHT-UHFFFAOYSA-N 2-(4-propan-2-yloxyphenoxy)terephthalic acid Chemical compound C1=CC(OC(C)C)=CC=C1OC1=CC(C(O)=O)=CC=C1C(O)=O FCRFNKDATPMHHT-UHFFFAOYSA-N 0.000 description 1
- BWQNFLHTXUROHY-UHFFFAOYSA-N 2-(4-propoxyphenoxy)terephthalic acid Chemical compound C1=CC(OCCC)=CC=C1OC1=CC(C(O)=O)=CC=C1C(O)=O BWQNFLHTXUROHY-UHFFFAOYSA-N 0.000 description 1
- XNVQESVVRUAJLN-UHFFFAOYSA-N 2-(6-cyano-9-oxoxanthen-2-yl)oxyethyl acetate Chemical compound N#CC1=CC=C2C(=O)C3=CC(OCCOC(=O)C)=CC=C3OC2=C1 XNVQESVVRUAJLN-UHFFFAOYSA-N 0.000 description 1
- DKDPSTQRGGVJIF-UHFFFAOYSA-N 2-[9-oxo-6-(2h-tetrazol-5-yl)xanthen-2-yl]oxyethyl butanoate Chemical compound C=1C=C2C(=O)C3=CC(OCCOC(=O)CCC)=CC=C3OC2=CC=1C1=NN=NN1 DKDPSTQRGGVJIF-UHFFFAOYSA-N 0.000 description 1
- VDNDSCHUKPWAGZ-UHFFFAOYSA-N 2-amino-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(N)=CC=C3OC2=CC=1C1=NN=NN1 VDNDSCHUKPWAGZ-UHFFFAOYSA-N 0.000 description 1
- DRAZMYVPAPBHLO-UHFFFAOYSA-N 2-ethoxy-6-(2h-tetrazol-5-yl)xanthen-9-one;sodium Chemical compound [Na].C=1C=C2C(=O)C3=CC(OCC)=CC=C3OC2=CC=1C=1N=NNN=1 DRAZMYVPAPBHLO-UHFFFAOYSA-N 0.000 description 1
- DXYXTQGHCHDDLO-UHFFFAOYSA-N 2-ethylsulfanyl-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(SCC)=CC=C3OC2=CC=1C=1N=NNN=1 DXYXTQGHCHDDLO-UHFFFAOYSA-N 0.000 description 1
- UARUNUKHGGPPHT-UHFFFAOYSA-N 2-methoxy-6-(2h-tetrazol-5-yl)xanthen-9-one;sodium Chemical compound [Na].C=1C=C2C(=O)C3=CC(OC)=CC=C3OC2=CC=1C=1N=NNN=1 UARUNUKHGGPPHT-UHFFFAOYSA-N 0.000 description 1
- COSLERGFSRDIIX-UHFFFAOYSA-N 2-nitro-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC([N+](=O)[O-])=CC=C3OC2=CC=1C1=NN=NN1 COSLERGFSRDIIX-UHFFFAOYSA-N 0.000 description 1
- LEJJPOOKJQJEAK-UHFFFAOYSA-N 2-propan-2-yloxy-6-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC(OC(C)C)=CC=C3OC2=CC=1C1=NN=NN1 LEJJPOOKJQJEAK-UHFFFAOYSA-N 0.000 description 1
- DRVNVHDSDVDAAG-UHFFFAOYSA-N 2-propoxy-6-(2h-tetrazol-5-yl)xanthen-9-one;sodium Chemical compound [Na].C=1C=C2C(=O)C3=CC(OCCC)=CC=C3OC2=CC=1C=1N=NNN=1 DRVNVHDSDVDAAG-UHFFFAOYSA-N 0.000 description 1
- AOFYKQRNJOGDLE-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)xanthen-9-one Chemical compound C=1C=C2C(=O)C3=CC=CC=C3OC2=CC=1C1=NN=NN1 AOFYKQRNJOGDLE-UHFFFAOYSA-N 0.000 description 1
- CFFJFHJPTPQSJA-UHFFFAOYSA-N 3-(6-cyano-9-oxoxanthen-2-yl)oxypropyl acetate Chemical compound N#CC1=CC=C2C(=O)C3=CC(OCCCOC(=O)C)=CC=C3OC2=C1 CFFJFHJPTPQSJA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QASBCTGZKABPKX-UHFFFAOYSA-N 4-(methylsulfanyl)phenol Chemical compound CSC1=CC=C(O)C=C1 QASBCTGZKABPKX-UHFFFAOYSA-N 0.000 description 1
- QEYQMWSESURNPP-UHFFFAOYSA-N 4-propan-2-yloxyphenol Chemical compound CC(C)OC1=CC=C(O)C=C1 QEYQMWSESURNPP-UHFFFAOYSA-N 0.000 description 1
- KIIIPQXXLVCCQP-UHFFFAOYSA-N 4-propoxyphenol Chemical compound CCCOC1=CC=C(O)C=C1 KIIIPQXXLVCCQP-UHFFFAOYSA-N 0.000 description 1
- CMUOWQLJDGSEHG-UHFFFAOYSA-N 7-methylsulfanyl-9-oxoxanthene-3-carbonitrile Chemical compound N#CC1=CC=C2C(=O)C3=CC(SC)=CC=C3OC2=C1 CMUOWQLJDGSEHG-UHFFFAOYSA-N 0.000 description 1
- YPJDLOUCRVCBPN-UHFFFAOYSA-N 7-methylsulfanyl-9h-xanthene-3-carbaldehyde Chemical compound O=CC1=CC=C2CC3=CC(SC)=CC=C3OC2=C1 YPJDLOUCRVCBPN-UHFFFAOYSA-N 0.000 description 1
- ZNHJWDMPUBTZGX-UHFFFAOYSA-N 7-methylsulfanyl-9h-xanthene-3-carbonitrile Chemical compound N#CC1=CC=C2CC3=CC(SC)=CC=C3OC2=C1 ZNHJWDMPUBTZGX-UHFFFAOYSA-N 0.000 description 1
- LHBRMPUFILSWCO-UHFFFAOYSA-N 9-oxo-7-propan-2-yloxyxanthene-3-carbonitrile Chemical compound N#CC1=CC=C2C(=O)C3=CC(OC(C)C)=CC=C3OC2=C1 LHBRMPUFILSWCO-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WQWNISLJIUQHAU-UHFFFAOYSA-N C(C)(=O)OCCOC1=CC=2C(C3=CC=C(C=C3OC2C=C1)C1=NN=NN1)=O.OCCOC1=CC=2C(C3=CC=C(C=C3OC2C=C1)C1=NN=NN1)=O Chemical compound C(C)(=O)OCCOC1=CC=2C(C3=CC=C(C=C3OC2C=C1)C1=NN=NN1)=O.OCCOC1=CC=2C(C3=CC=C(C=C3OC2C=C1)C1=NN=NN1)=O WQWNISLJIUQHAU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 238000006214 Clemmensen reduction reaction Methods 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000006547 Leuckart Thiophenol synthesis reaction Methods 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- HRRNDJCOCXWLCS-UHFFFAOYSA-N O.O.[Na].C1=CC=CC=2OC3=CC=CC=C3C(C12)=O Chemical compound O.O.[Na].C1=CC=CC=2OC3=CC=CC=C3C(C12)=O HRRNDJCOCXWLCS-UHFFFAOYSA-N 0.000 description 1
- JBZRLVKMCLOFLG-UHFFFAOYSA-N O=S=Cl Chemical compound O=S=Cl JBZRLVKMCLOFLG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- QHMZSTKAJPTZSD-UHFFFAOYSA-N [Na].C(C)OC(C1=C(C=C(C(=O)OCC)C=C1)SC1=CC=C(C=C1)CC)=O Chemical compound [Na].C(C)OC(C1=C(C=C(C(=O)OCC)C=C1)SC1=CC=C(C=C1)CC)=O QHMZSTKAJPTZSD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- GGISZLOBBISXOZ-UHFFFAOYSA-N acetic acid;chloroform Chemical compound CC(O)=O.ClC(Cl)Cl GGISZLOBBISXOZ-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- PAYWCKGMOYQZAW-UHFFFAOYSA-N dimethyl 2-nitrobenzene-1,4-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C([N+]([O-])=O)=C1 PAYWCKGMOYQZAW-UHFFFAOYSA-N 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 150000002464 imidothioesters Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940080428 lactose 200 mg Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000019980 sodium acid phosphate Nutrition 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- HIVDMVZJKJRWCZ-UHFFFAOYSA-M sodium;3-hydroxy-2-methylthiobenzate Chemical compound [Na+].CC1=C(O)C=CC=C1C([O-])=S HIVDMVZJKJRWCZ-UHFFFAOYSA-M 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 150000003681 vanadium Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D311/86—Oxygen atoms, e.g. xanthones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000514519A CA1229304A (en) | 1982-04-27 | 1986-07-23 | Tricyclic compounds and their use |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8212139 | 1982-04-27 | ||
| GB8212139 | 1982-04-27 | ||
| GB8230055 | 1982-10-21 | ||
| GB8230055 | 1982-10-21 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000514519A Division CA1229304A (en) | 1982-04-27 | 1986-07-23 | Tricyclic compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1222516A true CA1222516A (en) | 1987-06-02 |
Family
ID=26282657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000426692A Expired CA1222516A (en) | 1982-04-27 | 1983-04-26 | Tricyclic compounds, and their preparation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4902701A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0093381B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU566167B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1222516A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3364674D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK185283A (cg-RX-API-DMAC7.html) |
| FI (1) | FI82832C (cg-RX-API-DMAC7.html) |
| GR (1) | GR78142B (cg-RX-API-DMAC7.html) |
| IE (1) | IE55228B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL68498A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ204003A (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8309260D0 (en) * | 1983-04-06 | 1983-05-11 | Erba Farmitalia | Condensed benzopyrone derivatives |
| GB8328494D0 (en) * | 1983-10-25 | 1983-11-23 | Wellcome Found | Liquid containment systems |
| US4861795A (en) * | 1988-06-23 | 1989-08-29 | Rorer Pharmaceutical Corporation | Treatment of conditions requiring enhanced oxygen availability to mammalian tissues |
| US4849416A (en) * | 1988-07-25 | 1989-07-18 | Rorer Pharmaceutical Corporation | Treatment of conditions requiring enhanced oxygen availability to mammalian tissues |
| US4996230A (en) * | 1990-02-16 | 1991-02-26 | Eli Lilly And Company | Leukotriene antagonists |
| IT1261662B (it) * | 1992-09-07 | 1996-05-28 | Inverni Della Beffa Spa | Derivati xantonici, loro preparazione ed attivita' |
| US5624794A (en) * | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
| US5977077A (en) * | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US6221637B1 (en) | 1996-03-05 | 2001-04-24 | Takeda Chemical Industries, Ltd. | Xanthene derivatives, their production and use |
| US6355153B1 (en) * | 1999-09-17 | 2002-03-12 | Nutool, Inc. | Chip interconnect and packaging deposition methods and structures |
| US7506438B1 (en) * | 2000-11-14 | 2009-03-24 | Freescale Semiconductor, Inc. | Low profile integrated module interconnects and method of fabrication |
| US8828226B2 (en) | 2003-03-01 | 2014-09-09 | The Trustees Of Boston University | System for assessing the efficacy of stored red blood cells using microvascular networks |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| JP2013507447A (ja) | 2009-10-12 | 2013-03-04 | ニュー ヘルス サイエンシーズ、インク． | 酸素減損装置及び赤血球から酸素を除去する方法 |
| CN102711865B (zh) | 2009-10-12 | 2015-08-19 | 新健康科学股份有限公司 | 具有氧和二氧化碳消耗能力的血液贮藏袋系统和消耗装置 |
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| US9339025B2 (en) | 2010-08-25 | 2016-05-17 | New Health Sciences, Inc. | Method for enhancing red blood cell quality and survival during storage |
| WO2012061731A1 (en) | 2010-11-05 | 2012-05-10 | New Health Sciences | Irradiation of red blood cells and anaerobic storage |
| US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
| ES2923571T3 (es) | 2011-08-10 | 2022-09-28 | Hemanext Inc | Dispositivo integrado de filtrado de leucocitos, oxígeno y/o CO2 y separación de plasma |
| PT2961269T (pt) | 2013-02-28 | 2021-12-16 | Hemanext Inc | Dispositivo de depleção de gás para produtos sanguíneos |
| ES2902499T3 (es) | 2015-03-10 | 2022-03-28 | Hemanext Inc | Kits desechables de reducción de oxígeno, dispositivos y procedimientos de uso de los mismos |
| KR102845950B1 (ko) | 2015-04-23 | 2025-08-12 | 헤마넥스트 인코포레이티드 | 혐기성 혈액 저장 용기 |
| KR102675532B1 (ko) | 2015-05-18 | 2024-06-13 | 헤마넥스트 인코포레이티드 | 전혈의 저장 방법, 및 그것의 조성물 |
| KR20240132129A (ko) | 2016-05-27 | 2024-09-02 | 헤마넥스트 인코포레이티드 | 혐기성 혈액 저장 및 병원체 불활성화 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2783246A (en) * | 1955-05-02 | 1957-02-26 | Allied Chem & Dye Corp | Manufacture of xanthene |
| BE759292A (fr) * | 1969-11-27 | 1971-05-24 | Allen & Hanburys Ltd | Derives de xanthone, leur preparation et leur emploi |
| US4061768A (en) * | 1971-09-08 | 1977-12-06 | Burroughs Wellcome Co. | Certain cyclic carbonyl compounds used in the prophylaxis of allergic conditions |
| AU478775B2 (en) * | 1974-09-13 | 1974-12-12 | Syntex Gu. S. A. ) Inc | Novel substituted xanthone carboxylic acid compounds |
-
1983
- 1983-04-26 GR GR71216A patent/GR78142B/el unknown
- 1983-04-26 AU AU13924/83A patent/AU566167B2/en not_active Ceased
- 1983-04-26 CA CA000426692A patent/CA1222516A/en not_active Expired
- 1983-04-26 IE IE949/83A patent/IE55228B1/en unknown
- 1983-04-26 FI FI831420A patent/FI82832C/fi not_active IP Right Cessation
- 1983-04-26 NZ NZ204003A patent/NZ204003A/en unknown
- 1983-04-26 DK DK185283A patent/DK185283A/da not_active Application Discontinuation
- 1983-04-26 IL IL68498A patent/IL68498A/xx unknown
- 1983-04-26 EP EP83104086A patent/EP0093381B1/en not_active Expired
- 1983-04-26 DE DE8383104086T patent/DE3364674D1/de not_active Expired
-
1986
- 1986-09-03 US US06/903,834 patent/US4902701A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK185283A (da) | 1983-10-28 |
| GR78142B (cg-RX-API-DMAC7.html) | 1984-09-26 |
| FI82832B (fi) | 1991-01-15 |
| DE3364674D1 (en) | 1986-08-28 |
| IE830949L (en) | 1983-10-27 |
| NZ204003A (en) | 1986-05-09 |
| IL68498A0 (en) | 1983-07-31 |
| US4902701A (en) | 1990-02-20 |
| AU1392483A (en) | 1983-11-03 |
| IE55228B1 (en) | 1990-07-04 |
| AU566167B2 (en) | 1987-10-08 |
| EP0093381B1 (en) | 1986-07-23 |
| IL68498A (en) | 1986-09-30 |
| FI831420A0 (fi) | 1983-04-26 |
| FI82832C (fi) | 1991-04-25 |
| EP0093381A1 (en) | 1983-11-09 |
| DK185283D0 (da) | 1983-04-26 |
| FI831420L (fi) | 1983-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1222516A (en) | Tricyclic compounds, and their preparation | |
| EP1353911B1 (en) | Antiviral agents | |
| FI71929B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara etrfoereningar samt vid deras framstaellning anvaendbara me llnprodukter | |
| JPS60246375A (ja) | ピリダジノン、その製法並びに該化合物を含有する気管支疾患治療剤 | |
| US3534055A (en) | Certain substituted 1-amino-1,2,3,4-tetrahydro naphthalenes and pharmaceutically acceptable salts thereof | |
| JPS61271287A (ja) | 血糖降下性チアゾリジンジオン | |
| US3976787A (en) | Pharmaceutical guanidine preparations and methods of using same | |
| US3905989A (en) | (Tetrazolyl)thioxanthone-10,10-dioxides | |
| JPS63222161A (ja) | 抗アレルギーおよび抗炎症剤として使用される新規なナフタレン誘導体 | |
| US4626432A (en) | Storage of red blood cells | |
| JPH0352874A (ja) | 置換ベンゾニトリル | |
| US3927023A (en) | Imidazolyl benzofurans | |
| US3709996A (en) | Pharmaceutical compositions containing n-cyclopropyl-1-aminoindane compounds and adapted for administration to obtain inhibition of monoamine oxidase enzyme and process | |
| HK10491A (en) | 7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid and 7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives, their preparation and use as medicaments | |
| CN112538069A (zh) | 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途 | |
| US4025635A (en) | Cyclic sulphur compounds | |
| US3915988A (en) | Benzopyranopyrazolecarboxylic acids | |
| JP2511204B2 (ja) | 置換インド―ル | |
| JPS6025969A (ja) | アレルギ−治療用組成物 | |
| CA1229304A (en) | Tricyclic compounds and their use | |
| JPH0692410B2 (ja) | 新規なベンゾフロキノリン誘導体 | |
| JPS5867618A (ja) | １―アザキサントンからなる医薬 | |
| US3984534A (en) | Tetrazolyl anthraquinones for inhibiting the release of spasmogen mediators | |
| IL28179A (en) | Antibiotic composition containing cephalosporin derivatives and new cephalosporin derivatives | |
| US4177257A (en) | Cyclic sulphur compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |